文献速递血栓与止血

意大利血友病患者对基因治疗的认知与态度队列研究

Knowledge and attitudes toward gene therapy of a cohort of Italian patients with hemophilia.
PubMed 文献 · J Thromb Haemost · 2023-12-22

该研究向意大利血友病A和B患者发放问卷,评估其对基因治疗的认知、接受意愿、预期获益与担忧。85例参与者(64例重型血友病A、4例重型血友病B)仅了解基因治疗的一般信息;54.4%受访者不愿接受基因治疗,主要因担心疗效随时间丧失、副作用及知识缺乏。知识水平越高,重型血友病患者对该疗法的接受度越高。

要点

  • 85例意大利血友病患者中,64例为重型血友病A、4例为重型血友病B。
  • 54.4%受访者对接受基因治疗持否定态度,主因担心疗效丧失、副作用及知识缺乏。
  • 知识水平越高,重型血友病患者对基因治疗的接受度越高。

核心结论

  • 总体而言,意大利血友病患者对基因治疗认知不足,但知识水平越高似乎与接受基因治疗的意愿越高相关。

研究设计与样本

  • 研究采用问卷对意大利血友病A和B患者进行调查,评估临床数据、基因治疗知识、接受意愿、感知获益与担忧及信息需求。
  • 共有85例患者参与研究,其中64例为重型血友病A、4例为重型血友病B。

主要发现

  • 参与者似乎仅了解基因治疗的一般信息,对其详细工作机制了解甚少。
  • 避免频繁输注和减少出血事件似乎是最相关的预期获益。
  • 基因治疗可能失败或随时间失去疗效是主要担忧。
  • 54.4%的受访者对接受基因治疗给出否定回答,主要原因是担心治疗随时间失去疗效、害怕副作用及缺乏基因治疗知识。
  • 在重型血友病患者中,知识水平越高,对该颠覆性疗法的接受度越高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gene therapy (GT) has recently become a new therapeutic option for hemophilia A and B. However, patient levels of knowledge and attitudes toward it are poorly understood. A general lack of knowledge and education has been highlighted in previous studies. To date, no studies focused on patient attitudes toward GT, priorities, concerns, and information needs, nor how these factors might influence their willingness to accept it. OBJECTIVES: To evaluate knowledge and attitudes toward GT of an Italian cohort of patients with hemophilia. METHODS: A questionnaire was administered to patients with hemophilia A and B to evaluate: (1) clinical data; (2) GT knowledge; (3) willingness to accept GT, perceived benefits and concerns, and information needs. RESULTS: Eighty-five patients participated in the study; 64 with severe hemophilia A and 4 with severe hemophilia B. Participants appeared to know only general information on GT, but little about its detailed functioning. The avoidance of frequent infusions and the reduction of bleeding episodes seem to be the most relevant expected benefits. The possibility of failing or losing effectiveness of GT over time was the main concern. Regarding willingness to undergo GT, 54.4% of respondents gave a negative response, mainly due to fear that treatment will lose effectiveness over time, fear of side effects, and lack of GT knowledge. Greater knowledge increased the acceptability of this disruptive therapy among patients with severe hemophilia. CONCLUSION: Overall, Italian patients with hemophilia showed poor knowledge of GT. However, it seems that greater knowledge was associated with a greater willingness to have GT.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Cutica I, Mortarino M, Garagiola I, et al. Knowledge and attitudes toward gene therapy of a cohort of Italian patients with hemophilia. J Thromb Haemost. 2023. PMID: 38142845. doi:10.1016/j.jtha.2023.12.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。